Jessica K. Gordon, MD

Dr. Jessica Gordon is an Assistant Attending in the Department of Rheumatology at Hospital for Special Surgery. She specializes in the treatment of various rheumatologic conditions including Scleroderma, Vasculitis, Systemic Lupus Erythematosus, Rheumatoid Arthritis, and many other conditions. Dr. Gordon is an investigator in several clinical trials and observational studies focusing on Scleroderma. She has been the recipient of numerous awards including a Scleroderma Foundation New Investigator Grant, the Charles L. Christian Award for Excellence in Musculoskeletal Research, and the American College of Rheumatology Distinguished Fellow Award.

Appointments

Assistant Attending Physician, Hospital for Special Surgery

Specialty

Rheumatology

Special Expertise

Scleroderma, Vasculitis, Systemic Lupus Erythamatosus, Inflammatory Arthritis

Awards

Charles L. Christian Award for Excellence in Musculoskeletal Research, 2010
Department of Medicine Fellow Award - Finalist, 2010
American College of Rheumatology Distinguished Fellow Award, 2009
Certificate of Appreciation – Scleroderma Foundation – Tristate Chapter, 2009
Donald Knowlan Award, Georgetown University Hospital, Dept. of Internal Medicine, 2005
Janet Glasgow Memorial Achievement Citation, American Medical Women’s Society, 2002
Alpha Omega Alpha Honor Society, 2001

Affiliations

Member, American College of Rheumatology
Member, American Medical Association

Procedures

Intra-articular and intra-bursal aspirations and injections

Languages

Spoken by Office Staff: Spanish

Education

MD, State University of New York at Stony Brook, Stony Brook, NY 2002

Internship

Internal Medicine, Georgetown University Hospital, Washington, DC

Residency

Internal Medicine, Georgetown University Hospital, Washington, DC

Fellowship

Rheumatology, Hospital for Special Surgery

Certification

Rheumatology, 2008
Internal Medicine, 2005

State Licensure

NY  

Selected Publications

• Gordon JK, Spiera RF. Targeting tyrosine kinases: a novel therapeutic strategy for systemic sclerosis. Curr Opin Rheumatol. 2010 Nov;22(6):690-5. PMID: 20827202
• Gordon JK, Magro CM, Lu T, Schneider R, Chiu A, Solomon G, Furman RR, Bass A, Erkan D. (2009)    Overlap Between Systemic Lupus Erythematosus and Kikuchi Fujimoto Disease: A Clinical Pathology Conference held by the Department of Rheumatology at Hospital for Special Surgery. HSS Journal.  Sep;5(2):169-77. PMID: 19609622
• Gordon JK, Magid SK, Maki R, Fleischer M, Berman E.  Elevations of Creatine Kinase in Patients Treated with Imatinib Mesylate (Gleevec.)  Leuk Res. 2010 Jun;34(6):827-9. PMID: 19963273
• Spiera RF, Gordon JK, Mersten JN, Magro CM, Mehta M, Wildman HF, Kloiber S, Kirou KA, Lyman S, Crow MK. Imatinib Mesylate (Gleevec™) in the Treatment of Diffuse Cutaneous Systemic Sclerosis: Results of a One Year, Phase IIa, Single Arm, Open Label Clinical Trial. Submitted to Annals of Rheumatic Disease.
• Gordon JK and Spiera RF. Biomarkers Imatinib and the Treatment of Fibrosis: Recent Trials and Tribulations. Current Rheumatology Reports. (In press.)
• Gordon JK and Spiera RF. Drug Evaluations: Imatinib mesylate: an investigational anti-fibrotic agent for the treatment of diffuse cutaneous systemic sclerosis. International Journal of Clinical Rheumatology (in press)

For more publications, please see the PubMed listing.

Selected Books/Chapters

• Gordon JK, Goldenberg D, Erkan D, Lockshin M.  (2009)  Difficult Situations in the Antiphospholipid Syndrome.  Handbook of Systemic Autoimmune Diseases, Volume 10. Antiphospholipid Syndrome in Systemic Autoimmune Diseases. (Eds. Ricard Cervera, Joan Carles Reverter and Munther Khamashta), 215 – 233.

Selected Presentations

• Gordon JK, Spiera RF, Mersten JN, Wildman HF, Taime Z, Hackett, NR, Vukelic S, Kirou K, Crow MK. Does Treatment with Imatinib Modify Gene Expression in the Skin and Peripheral Blood Mononuclear Cells of Patient with Systemic Sclerosis? American College of Rheumatology Scientific Meeting (Atlanta, GA, 2010.)
• Gordon JK, Gomberg-Maitland M, Segal B, Domsic R, Shah A, Hummers L, Steen V, Horn E and the PHAROS Investigators. Difficulty Using World Health Organization Criteria to Categorize Pulmonary Hypertension in Patients with Systemic Sclerosis. American College of Rheumatology Scientific Meeting (Atlanta, GA, 2010.)
• Spiera RF, Gordon JK, Mersten J, Magro CM, Mehta M, Wildman HF, Kloiber SA, Kirou KA, Lyman, S, Crow MK. Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis: Interim Results of a Phase IIa, One Year, Open Label Clinical Trial. American College of Rheumatology Scientific Meeting (Atlanta, GA, 2010.)
• Gordon JK,  Vukelic S, Magro CM, Mersten J, Wildman HF, Crow MK, Kirou KA and Spiera RF.  Histologic and Molecular Basis of Improved Skin Scores in Scleroderma Patients Treated with Imatinib Mesylate (Gleevec.) Abstract 1727.  American College of Rheumatology Scientific Meeting (Philadelphia, PA, 2009.)
• Gordon JK, Mersten J, Lyman S, Kloiber SA, Wildman HF, Crow MK, Kirou KA and  Spiera RF.  Imatinib Mesylate (Gleevec) in the Treatment of Systemic Sclerosis: Interim Results of a Phase IIa, One Year, Open Label Clinical Trial.  Presentation 606. American College of Rheumatology Scientific Meeting (Philadelphia, PA, 2009.)
• Taimeh Z, Gordon JK, MacDermott EJ, Barillas L, Mersten J, Duculan R, Spiera RF, Crow MK, Kirou KA. Elevated sVEGFR-1 Is a Candidate Biomarker for Pulmonary Dysfunction in Patients with Systemic Sclerosis.  Abstract 466. American College of Rheumatology Scientific Meeting (Philadelphia, PA, 2009.)
• Spiera RF Gordon JK Mehta M Kirou KA Lyman S Kloiber SA Crow MK. (2008).  Phase IIa Trial of Imatinib Mesylate (Gleevec) in the Treatment of Diffuse Systemic Sclerosis - An Interim Analysis. Arthritis and Rheumatism 58(10): S1222.
• Gordon JK, Magid S, Berman E. (2008). Elevations in Creatine Kinase Occur Frequently in Patients Treated with Imatinib Mesylate (Gleevec.) Abstract F15/469, American College of Rheumatology Scientific Meeting (San Francisco, CA, 2008.)
• Gordon JK, Taimeh Z, Markopoulou A, Mersten J, Crow MK, Kirou KA.  (2008). High Levels of Activated ERK in Monocytes of Patients with Scleroderma. Abstract F2/456, American College of Rheumatology Scientific Meeting (San Francisco, CA, 2008.)
• Gordon JK, Steen V. (2005).  African American Scleroderma Patients Have Altered Body Image. Arthritis and Rheumatism 52(9): S585.
  

 

Research Interests

Scleroderma, Vasculitis